Dr. Pecora on the CPIT001 Study in Hematologic Malignancies

Andrew L. Pecora, MD
Published: Friday, Dec 15, 2017



Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the CPIT001 study for patients with hematologic malignancies.

The CPIT001 trial is investigating the safety and efficacy of the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) following autologous stem cell transplant in patients with high-risk hematologic malignancies. The first 29 patients enrolled experienced adverse events but those were not unexpected, says Percora.
 
SELECTED
LANGUAGE


Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the CPIT001 study for patients with hematologic malignancies.

The CPIT001 trial is investigating the safety and efficacy of the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) following autologous stem cell transplant in patients with high-risk hematologic malignancies. The first 29 patients enrolled experienced adverse events but those were not unexpected, says Percora.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication
x